These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34074983)

  • 41. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
    Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
    Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
    Jin Y; Lin Y; Lin LJ; Zheng CQ
    World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis.
    Kobayashi K; Suzuki Y; Watanabe K; Oda K; Mukae M; Yamada A; Yamagami H; Nishimura A; Okamoto H
    J Clin Pharmacol; 2019 Feb; 59(2):271-279. PubMed ID: 30192378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report.
    Goetgebuer RL; Masclee GMC; van der Eijk AA; van der Woude CJ; de Man RA; de Vries AC
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101948. PubMed ID: 35659604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
    Hoffmann P; Krisam J; Stremmel W; Gauss A
    Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis.
    Dalal RS; Goksel B; Hamilton MJ
    Dig Dis Sci; 2023 May; 68(5):1709-1713. PubMed ID: 36929242
    [No Abstract]   [Full Text] [Related]  

  • 51. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
    Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
    J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.
    McLean LP; Shea-Donohue T; Cross RK
    Immunotherapy; 2012 Sep; 4(9):883-98. PubMed ID: 23046232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
    Card T; Ungaro R; Bhayat F; Blake A; Hantsbarger G; Travis S
    Aliment Pharmacol Ther; 2020 Jan; 51(1):149-157. PubMed ID: 31747086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psoriasis Induced by Vedolizumab.
    Sody E; Körber A
    Inflamm Bowel Dis; 2017 Feb; 23(2):E9-E11. PubMed ID: 28107281
    [No Abstract]   [Full Text] [Related]  

  • 57. Vedolizumab-induced cholestatic liver injury.
    Rojas-Feria M; Rodríguez-Fernández M; Castro-Fernández M; Suárez-García E
    Gastroenterol Hepatol; 2022 Jan; 45(1):64-65. PubMed ID: 33248173
    [No Abstract]   [Full Text] [Related]  

  • 58. Vedolizumab-Associated Pancreatitis in Paediatric Ulcerative Colitis: Functional Selectivity of the α4β7integrin and MAdCAM-1 Pathway?
    Lopez RN; Gupta N; Lemberg DA
    J Crohns Colitis; 2018 Mar; 12(4):507-508. PubMed ID: 29228226
    [No Abstract]   [Full Text] [Related]  

  • 59. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.